Analysts Set BioLife Solutions, Inc. (NASDAQ:BLFS) Price Target at $27.50

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have received an average rating of “Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have covered the stock in the last year is $27.50.

A number of analysts have weighed in on the stock. Northland Securities raised their price objective on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Craig Hallum raised their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright reduced their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Finally, TD Cowen lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th.

BioLife Solutions Trading Up 1.1 %

NASDAQ BLFS opened at $27.47 on Friday. The firm has a market cap of $1.27 billion, a PE ratio of -25.92 and a beta of 1.88. BioLife Solutions has a 1-year low of $11.91 and a 1-year high of $28.88. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The stock has a 50-day moving average of $24.23 and a 200-day moving average of $23.24.

Insider Activity

In other news, CRO Garrie Richardson sold 3,070 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $25.12, for a total transaction of $77,118.40. Following the completion of the transaction, the executive now directly owns 114,773 shares of the company’s stock, valued at approximately $2,883,097.76. This trade represents a 2.61 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Aby J. Mathew sold 25,000 shares of BioLife Solutions stock in a transaction on Friday, November 15th. The shares were sold at an average price of $21.17, for a total value of $529,250.00. Following the completion of the transaction, the executive vice president now owns 302,046 shares of the company’s stock, valued at approximately $6,394,313.82. The trade was a 7.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,313 shares of company stock worth $1,572,899 over the last 90 days. Company insiders own 2.20% of the company’s stock.

Institutional Trading of BioLife Solutions

Hedge funds have recently added to or reduced their stakes in the business. Stifel Financial Corp increased its position in shares of BioLife Solutions by 5.4% in the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after acquiring an additional 670 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in BioLife Solutions by 4.0% in the second quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider’s stock valued at $392,000 after purchasing an additional 700 shares in the last quarter. GAMMA Investing LLC lifted its stake in BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 748 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of BioLife Solutions by 5.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock valued at $296,000 after purchasing an additional 753 shares in the last quarter. Finally, Mark Sheptoff Financial Planning LLC bought a new stake in BioLife Solutions during the 3rd quarter worth $28,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.